Systemicsclerosis(SSc)isaconnectivetissuediseaseofunknownetiology,manifestinginpatientsastissuefibrosis,endothelialdysfunction,andinflammation.Thediseaseischaracterizedbyautoantibodies,ahallmarkof autoimmunity.Variouscytokinesandgrowthfactorsareelevatedinthesystemiccirculationandfibroticlesions ofpatientswithSSc.Inparticular,severalstudiesoverthepast2decadeshaveshownthatinterleukin-6(IL-6) appearstobeinvolvedinthepathogenesisofSSc.BasedontheassociationbetweenaberrantIL-6production andtissuefibrosisinpatientswithSSc,theanti-IL-6receptorantibody,tocilizumab,isbeinginvestigatedinclinical trials.ThisarticlereviewsthebiologicalfeaturesofIL-6andtheIL-6receptor;theroleofIL-6inthepathogenesis ofSSc;andthepotentialforIL-6inhibitiontobeusedinthetreatmentofpatientswithSSc.
REVIEW
fibrosisandendothelialdamage (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) .Thefindingsofthese experimental studies provided the rationale for developing noveltargetedtherapiesinSSc,whichhavebeenevaluatedin severalclinicaltrialsinthepastdecade;however,adiseasemodifyingtherapyhasyettobeapprovedforthisindication. In a recent randomized, double-blind, placebo-controlled, phase2trial,tocilizumab,ananti-IL-6receptor-alpha(IL-6Rα) antibody,wasinvestigatedasatreatmentforskinfibrosisin patients with SSc and was shown to reduce skin thickening andimprovelungfunction (29) .
This article reviews the biological and physiological fea-turesofIL-6andrelatedpeptidesanditsroleinthepatho-genesisofSSc.
Biological activity of IL-6
Acute phase response IL-6isapleiotropicandpro-inflammatorycytokinethatis producedbybothlymphoidandnonlymphoidcells (30) and isassociatedwithawiderangeofbiologicalfunctions.Interferon-beta 2 (IFN-β2), B-cell stimulatory factor type 2, and hepatocyte-stimulatingfactor,wereeachoriginallyidentified in the 1980s as distinct proteins (31) (32) (33) . Molecular cloning ofthesemoleculesrevealedthattheywereinfactidentical, resultinginthis26-kDapeptidebeingreferredtouniversally asIL-6sincelate1988 (34) .
The biosynthesis of acute phase proteins, including C-reactive protein, fibrinogen, α1-acid glycoprotein, amyloid protein,andglobulinbyhepatocytesisregulatedbyIL-6and, to a lesser extent, by IL-1 and tumor necrosis factor (TNF) (35) (36) (37) .FurtherdemonstratingthekeyroleofIL-6intheacute phase response, IL-6-deficient mice exhibited a severely defective inflammatory acute phase response following tissue
Introduction
Systemic sclerosis (SSc) is a complex disease resulting from impaired biological cell function, affecting endothelial cells,fibroblasts,lymphocytes,monocytes,andbonemarrow cells (1) (2) (3) (4) .Vasculopathyandtissuefibrosisoccurasaresult oftheseimpairmentsandareconsideredtobethemainclini-calfeaturesofpatientswithSSc.Thesepatientshavedysregulation of genetic and epigenetic function (5-7), innate immunity(8),andresponsetoinfections,resultinginaberrant immuneactivationandacceleratedtissuedamageleadingto tissuefibrosis,vasculopathy,andautoimmunity.Inthepast2 decades,manycytokines (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) ,chemokines (19) (20) (21) ,growth factors (22) (23) (24) (25) (26) ,andtranscriptionfactors (27, 28) havebeen studied for their potential involvement in the pathogenesis of SSc. For example, in vitro and in vivo experiments using sclerodermamurinemodelshaverevealedthattransforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and connective tissue growth factor may play crucial roles in collagen production by tissue fibroblasts in SSc (22) (23) (24) (25) (26) .Inadditiontothesegrowthfactors,cytokines-including interleukin-1 (IL-1), IL-2, IL-4, IL-6, IL-8, IL-13, IL-33, and IL-35 -were found to be potent regulators of tissue
Immune response
B cells play a central role in antibody (immunoglobulin) productionunderthecontrolofvariouscytokinesproduced by T cells and macrophages. IL-6 was identified as a helper factor in monocyte supernatants, mediating phytohemagglutinin-induced T-cell activation and proliferation (39) . Furthermore,IL-6wasshowntoplayaroleinthelatephase of Staphylococcus aureus Cowan I stimulation of normal B cells, which resulted in their differentiation into immunoglobulin-G-producing cells (40) . An in vitro study in periph-eralmurineTcellsdemonstratedthatIL-6isinvolvedin T-cell proliferationbystimulatingIL-2productioninactivatedTcells (41) .ThisinvolvementofIL-6inT-celldevelopmentandfunction was thought to occur through the stimulation of T-cell activation, proliferation, and differentiation through both IL-2-dependent and -independent pathways (42) . IL-6 has also been shown to induce the differentiation of cytotoxic Tlymphocytes(CTLs)inthepresenceofIL-2 (43, 44) andis thought to act as a differentiation factor for CTLs, resulting intheinductionofserineesteraseandperforinexpressionin thegranulesofthesecells,whicharerequiredformediating targetcelllysis (45, 46) .
Hematopoiesis

IL-6canstimulatehematopoieticstemcellsinvitroand
can synergize with macrophage colony-stimulating factor ( M-CSF) under stimulation by macrophage colony forming units, affecting both the number and the size of macrophagecolonies (47) .IL-6hasalsobeenfoundtoactsynergistically with granulocyte-macrophage colony stimulating factor( GM-CSF) toactonmyeloidhematopoieticprogenitorcells (48) .
IL-6isinvolvedinthematurationofmegakaryocytesand promotestheproductionofplatelets,suggestingthatitfunctionsasathrombopoieticfactor (49) .Theadministrationof IL-6wasshowntoincreasethenumberofplateletsinboth mice and monkeys. Human megakaryocytes have been ob-servedtoexpresstheIL-6receptorandtoproduceIL-6,suggesting that IL-6 may regulate the terminal maturation of megakaryocytesinanautocrinemanner (50) .
Other responses
The potential involvement of IL-6 in proliferative glomerulonephritissuggeststhatthiscytokinemayinducethe proliferation of kidney mesangial cells (51) . Indeed, IL-6 transgenic mice exhibit mesangial proliferative glomerulonephritis, which was prevented by the anti-IL-6R antibody (51) . IL-6 may also directly influence osteoclast developmentandmayplayaroleinpostmenopausalosteoporosis. Inaninvivoexperiment,micethatunderwentovariectomy exhibitedanenhancementofosteoclastdevelopment;this phenomenon was prevented by the administration of an anti-IL-6antibody(52).
The IL-6 receptor
The IL-6 receptors consist of 2 subtypes -an 80-kDa IL-6-bindingprotein(IL-6Rchain)anda130-kDasignaltransducer(gp130)-eachofwhichhasthe4conservedcysteine residuesandatryptophan-serine-X-tryptophan-serinemotif thatcharacterizesmembersofthecytokinereceptorfamily (53) (54) (55) .IthasbeenestablishedthatIL-6isunabletodirectly bind to gp130 and that IL-6 binding to IL-6R is required to generatethehigh-affinitycomplexofIL-6/IL-6R/gp130 (56) . IL-6R is also expressed as a soluble form, and the complex of IL-6 and soluble IL-6R can generate IL-6-mediated signal transductionthroughgp130 (57) .Aschematicrepresentation ofcomplexformationbetweenIL-6andthetransmembrane orsolubleformofIL-6RisshowninFigure1.
Signal transduction of IL-6
ThebindingofIL-6toIL-6Randthesubsequentassocia-tionwithgp130inducestheformationofahexamerwitha 2:2:2 stoichiometry (58). Although IL-6R lacks a kinase domain, gp130 has several tyrosine kinases, Janus kinase 1 (JAK1) and JAK2. Binding of IL-6 and IL-6R induces homodi-merizationofgp130andphosphorylationofJAKs (59) .Inaddition,signaltransducerandactivatoroftranscription(STAT) playsacentralroleinthiscytokinesignaltransductionpathway,mainlythroughSTAT3 (60) .
ThesignaltransductionofIL-6isnegativelyregulatedby 2familiesofinhibitors:thesuppressorofcytokinesignaling (SOCS)andtheproteininhibitorsofactivatedSTAT(PIAS).The SOCSfamilyischaracterizedbyacentralSH2domainflanked byanN-terminalregioncontainingaconservedmotif,known asaSOCSbox (61) .UnliketheSOCSfamily,PIASconstitutesa familyofconstitutivelyexpressednegativeregulatorsofSTATmediated gene activation (62) . Five members of PIAS have beenidentifiedwithasharedhomologyandthepresenceof severalhighlyconserveddomains (62) .
Elevation of IL-6 in SSc
Elevated levels of serum IL-6 in patients with SSc have beenreportedinseveralstudies (10) (11) (12) (13) 15, (63) (64) (65) .Signifi-cantlyhigherlevelsofsolubleIL-6Randanti-IL-6autoantibod-ieshavealsobeenreportedinpatientswithSSccompared with healthy controls (66, 67) . The complex of IL-6-soluble IL-6R,andIL-6-anti-IL-6autoantibodycanbindtogp130and induce signal transduction in SSc (68, 69) . Significant cor-relationshavebeenobservedbetweenserumlevelsofIL-6 andtheseverityofskinthickening(70),diseaseprogression ininterstitiallungdisease(63),andcardiacinvolvement(64, 65);thesecomplicationsofSScarecharacterizedbytissuefibrosis.InadditiontoelevatedcirculatingIL-6levels,cultured fibroblastsfromSScpatientswerefoundtoexpressstrikingly high levels of IL-6 at both the transcriptional and the proteinlevels (71) (72) (73) (74) .InhibitionofIL-6signaltransductionusing ananti-IL-6antibodyattenuatedcollagenproductionincul-turedfibroblastsofSScpatients (14) . Additionally,elevated secretion of IL-6 from peripheral monocytes was observed inpatientswithSSc-associatedinterstitiallungdisease (75) . IncreasednumbersofperipheralBcellsandhigherIL-6levels were observed in SSc patients compared with healthy subjects, along with increased in vitro fibroblast proliferationandcollagenproductionwhennormalandscleroderma fibroblastswereexposedtoB-cellsupernatantsfromthese patients (76) . B cell activating factor (BAFF) is a cytokine thatisprimarilyproducedbymonocytes,macrophages,and myofibroblasts and is implicated in the regulation of B cell survival,activation,proliferation,andmaturation (77) . Serum levelsofBAFFwereelevatedinpatientswithSScandcorre-latedwiththeextentofskinfibrosisinSSc (78) .Moreover,it wasreportedthatBAFFmRNAlevelsinmonocytesinpatients with SSc, especially in IFN type I signature positive monocytes (79) .BAFFreceptor(BAFFR)wasalsooverexpressedin BcellsofpatientswithSSc (80) .Thoseobservationssuggest that the signal transduction through BAFF/BAFFR may contribute to the activation of B cells in SSc. The activation of B cells is one of the key pathways to induce excessive IL-6 productioninSSc.
Insummary,highconcentrationsofIL-6arefoundinthe seraofSScpatients (10) (11) (12) (13) 15, (63) (64) (65) andhavebeenshown tobehighlycorrelatedwiththeseverityoftissuefibrosis.In vitroexperimentsfurthersupporttheseobservations,dem-onstratinganincreasedsecretionofIL-6byculturedskinfibroblasts,monocytes,andBlymphocytesfrompatientswith SSc (71) (72) (73) (74) (75) (76) .Inparticular,theoverproductionofIL-6canlead to excessive collagen production by fibroblasts, which con-tributestotissuefibrosisinSSc (11, 13, 14) (Fig.2 ).
Precise mechanisms of upregulation of IL-6
As previously noted, the sources of IL-6 in the systemic circulation of patients with SSc may be fibroblasts, mono-cytes,andBcells.Infibroblasts,intracellularIL-1α(pro-IL-1α) wasshowntobeconstitutivelyexpressed,andtheautocrine effectofpro-IL-1αinducedtheproductionofIL-6,whichwas inhibitedbyuseofanantisenseoligodeoxynucleotidecom-plementarytoIL-1αmRNA (14) .Furthermore,IL-6production was found to be enhanced by PDGF in cultured fibroblasts from SSc patients and could be inhibited by an IL-1 receptor antagonist (81) . These observations indicate that PDGF-inducedIL-6overexpressionismediatedthroughtheaction ofIL-1.Anotherstudyreportedthattheincreasedexpression ofCD40onthesurfacesofskinfibroblasts,coupledwithits interaction withCD154,inducedIL-6production inpatients with SSc (82) . Recently, an autotaxin-lysophosphatidic acid pathwayinducedIL-6productioninSScfibroblasts,suggestingthattheautotaxin/lysophosphatidicacid/IL-6axisisfundamentaltothedevelopmentandprogressionoffibrosisin SSc(83).
Effects of IL-6 on fibrosis
IL-6isapotentinducerofcollagenproductioninfibroblasts, throughdirectandindirectmechanisms.Itiswellknownthat IL-6inducestheexpressionofprocollagenmRNAthroughthe phosphorylationofJAK,extracellularsignal-regulatedkinase, and mitogen-activated protein kinase (84) (85) (86) . IL-6 also en-hancesTGF-β,whichisastronginducerofcollagenproduction (87) . In addition to enhanced collagen production, the establishment of tissue fibrosis occurs because of a lack of balanceddegradationoftheextracellularmatrix,whichmay bestrictlycontrolledbymatrixmetalloproteinasesandtissue inhibitorsofmetalloproteinases(TIMPs)(3).IL-6significantly increases TIMP-1 synthesis through the phosphorylation of STAT3,resultingincollagenaccumulation (88) .Furthermore, IL-6increasesthepopulationofmyofibroblastsdifferentiated fromnormalfibroblasts(89),andthesemyofibroblastsplaya crucialroleintissuefibrosis.
Therapeutic effects of inhibiting IL-6 action in SSc
TheinvolvementofIL-6inSSc-associatedtissuefibrosis makesitarationaltherapeutictarget (90) (91) (92) .Otherautoimmune diseases -such as rheumatoid arthritis, Sjögren's syndrome (93) ,vasculitis (94) ,andgraft-versus-hostdisease (95)-canbetreatedbyblockingtheactionofIL-6 (96, 97) . Monoclonal anti-IL-6 antibodies have previously been developed to inhibit the signal transduction of IL-6, but this strategy failed in the initial clinical trials. Another avenue that was explored involved targeting the receptor instead ofthecytokineitself.Tocilizumab,ahumanizedmonoclonal antibodyagainstIL-6Rα,wasgeneratedandtestedinclinical trialsforthetreatmentofrheumatoidarthritis,demonstrat-ingefficacyandsafetysimilartothatofTNF-αantagonists (98, 99) .Currently,tocilizumabisapprovedforthetreatment of patients with rheumatoid arthritis, polyarticular or systemicjuvenileidiopathicarthritis,and,mostrecently,giant cellarteritis(100).CasereportsofSScpatientstreatedwith tocilizumab8mg/kgevery4weeksreportedskinsoftening (101),thinningofcollagenfiberbundlesinthedermis (101) , and improvements in joint mobility (102) . These were the firstreportstodemonstratepreliminaryevidenceofefficacy fortocilizumabinpatientswithSSc.Aphase2randomized controlledtrialevaluatingsubcutaneoustocilizumabforthe treatmentofSScwassubsequentlyconducted (29) ,reportingreductionsinskinthickening.Thesepromisingfindings supported the continued development of tocilizumab for thetreatmentofSSc,whichisbeinginvestigatedinaphase 3trial.
SimilartothedirectsuppressionofIL-6andIL-6R,inhibition of IL-6/IL-6R/gp130 signal transduction has the poten-tialtobeanovelstrategyforthetreatmentofSSc.Arecent investigationrevealedthattheinhibitionofJAK-2prevented bleomycin-induced fibrosis in mice and reduced skin fibro-sisinTSK-1mice (84) .Inaddition,thepathwayofJAK-STAT3 promotescollagensynthesis,proliferation,andmigrationof fibroblastsinfibroticdiseases,includingSScandkeloid.Aberrantactivationofthispathwayalsohasbeenreportedinthe skinofSScpatients,particularlyinfibroblasts.
Rituximab(anti-CD20antibody)isaB-celldepletionther-apythatmaybeusefulinthetreatmentofpatientswithSSc.
A multicenter, open-label, comparative study of rituximab versus conventional treatment reported that rituximab had abeneficialeffectonlungfunctionandskinthickeninginSSc (103) .Inaddition,B-celldepletioninpatientswithSScresult-edinthedecreaseofserumIL-6(104).Therefore,thebeneficialeffectsofrituximabontissuefibrosismaybeexplainedby theinhibitionofIL-6productionfromBcells.
Conclusion
IL-6 was initially reported as a B-cell stimulating factor that plays a crucial role in B-cell differentiation and immunoglobulinproduction.However,furtherresearchhasmade significantadvancesinthecharacterizationofthebiological featuresofIL-6,theIL-6signalingpathway,IL-6synthesis,and thecellstargetedbyIL-6.Amongthem,fibroblastsarebotha sourceofIL-6synthesisandatargetforIL-6throughitsspecificreceptor.InadditiontoTGF-β,IL-6isastrongregulatorof tissuefibrosisinpatientswithSSc.Althoughseveraltherapies inhibiting TGF-β have not affected tissue fibrosis in SSc patientsinclinicaltrials,IL-6-blockingtherapyusingtocilizumab mayhavepotentialforthetreatmentforskinandlungfibro-sisinpatientswithSSc.
